01 Growing Adoption of Advanced Insulin Delivery Technologies Insulin therapy is increasingly being supported by delivery technologies designed to improve dosing convenience, accuracy, and adherence. Insulin pens, connected pens, and other digitally enabled delivery systems are gaining attention as diabetes management increasingly shifts toward patient self-management outside traditional clinical settings. The integration of dose tracking and digital connectivity is also creating opportunities to link insulin administration with broader diabetes monitoring and care platforms. In August 2026, the global insulin pens market was projected to reach USD 9.25 billion in 2026 and expand at a CAGR of 8.18% through 2034, reflecting increasing demand for convenient insulin administration technologies.
02 Increasing Development and Adoption of Biosimilar Insulins Biosimilar insulin development is gaining importance as healthcare systems seek more affordable alternatives to established insulin products. Additional manufacturers entering the insulin market can increase competition, expand treatment options, and potentially reduce costs for patients and payers. Growing regulatory experience with biosimilar products is also supporting the expansion of insulin alternatives across different markets and treatment settings. In July 2025, the U.S. Food and Drug Administration approved Merilog, the first rapid-acting insulin biosimilar referencing insulin aspart, expanding the availability of biosimilar insulin options in the United States.
01 Rising Global Diabetes Prevalence Sustains Demand for Insulin Therapy The expanding global diabetes population is increasing the number of patients who require insulin for blood glucose management. Insulin remains essential for people with type 1 diabetes and is also required by many individuals with advanced type 2 diabetes when other therapies are insufficient to achieve adequate glycemic control. Increasing diagnosis, longer patient lifespans, and growing diabetes prevalence across low-, middle-, and high-income countries are therefore supporting sustained demand for insulin products.
01 High Insulin Prices and Unequal Access Restrict Market Penetration Insulin affordability remains a major barrier to treatment access, particularly in low- and middle-income countries where patients may face substantial out-of-pocket costs and limited availability. Differences in procurement systems, supply chains, reimbursement policies, and product prices can restrict consistent access to insulin even when clinical demand is high. These affordability and availability constraints can limit the conversion of unmet treatment needs into actual insulin consumption.
01 Expansion of Insulin Access in Emerging Markets Creates Growth Opportunities Improving insulin availability across underserved markets creates significant opportunities for manufacturers, distributors, and healthcare systems. Expansion of primary healthcare infrastructure, better procurement practices, broader insurance coverage, local manufacturing, and wider availability of affordable insulin formulations can increase treatment uptake.
01 Complex Supply Chains and Concentrated Manufacturing Create Insulin Supply Risks Insulin production requires specialized biological manufacturing capabilities, stringent quality controls, cold-chain handling, and reliable distribution infrastructure. Concentration of production among a limited number of major manufacturers can increase the potential impact of manufacturing disruptions, procurement issues, or supply-chain bottlenecks.
June 2026 Eli Lilly expanded its insulin portfolio with continued investments in next-generation insulin manufacturing and diabetes care solutions. The company focused on improving insulin production capacity, treatment accessibility, and advanced diabetes management options.
March 2026 Novo Nordisk expanded its insulin production capabilities through manufacturing investments and technology upgrades. The initiatives support increased supply of recombinant insulin products and strengthen global diabetes care infrastructure.
January 2026 Sanofi expanded its diabetes care portfolio with continued development and commercialization of insulin therapies. The company focused on improving treatment options, patient access, and personalized diabetes management solutions.
October 2025 Biocon Biologics expanded its recombinant insulin portfolio through additional market launches and regulatory advancements. The company continued strengthening its position in affordable insulin products and biosimilar diabetes treatments.